11:53 AM EDT, 08/13/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Wednesday said it has been accepted into Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 cohort program.

The program aims to accelerate the clinical development of Bria-OTS+, BriaCell's personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer and prostate cancer.

"We believe Bria-OTS+ has the potential to transform cancer care, offering meaningful advances in efficacy and safety for thousands of patients," said Dr. Miguel Lopez-Lago, BriaCell's chief scientific officer. "Our participation in this cohort program is yet another step towards achieving that vision."

BriaCell shares were last seen down $0.03 to $0.97 on the Toronto Stock Exchange.

Price: 0.97, Change: -0.03, Percent Change: -3.00